DadFinStart your free week
DadFin › Stocks › Healthcare › PAHC

Phibro Animal Health Corporation (PAHC) stock score

Healthcare · Drug Manufacturers - Specialty & Generic · United States

$38.30 ▲ +2.41% today

97.2
Dad Score, out of 100
strong

Phibro Animal Health Corporation (PAHC) is a Drug Manufacturers - Specialty & Generic company in the Healthcare sector, listed in the United States. On DadFin's weekly run it scores 97.2 out of 100 on the Dad Score, a strong reading that places the business ahead of 97% of the 5,774 US and Canadian stocks DadFin fully scores. Inside Healthcare it ranks #27 of 974. Its strongest axes are valuation, quality and growth; its weakest is liquidity.

Scores from the run of Oct 4, 2026. The Dad Score answers one question: how good is this business, measured against its own sector. How it is built →

The eight axes

Valuation
Strong
Quality
Above average
Growth
Above average
Price action
Above average
Risk
Above average
Conviction
Above average
Liquidity
Below average
Macro
Above average

Each axis is ranked inside the stock's own sector. Subscribers see the percentile and every input behind each bar.

Key numbers

P/E (trailing)15.3×
P/E (forward)9.7×
Dividend yield1.34%
Return on capital15.3%
Operating margin10.6%
Revenue growth (YoY)+17.1%
FCF yield0.4%
Net debt / EBITDA2.91×
Piotroski F-Score7 / 9
52-week change-0.2%
Market cap$1.5B
Next earningsNov 4, 2026

What subscribers see on PAHC

Start your free weekSubscriber? Open the full research →

Drug Manufacturers - Specialty & Generic peers

StockCompanyDad ScoreBandMarket cap
TAKTakeda Pharmaceutical Company Limi32.9weak$57.1B
TEVATeva Pharmaceutical Industries Lim93.6strong$46.1B
HLNHaleon plc64.5middling$38.7B
ZTSZoetis Inc.61.2middling$28.8B
UTHRUnited Therapeutics Corporation99.8strong$23.2B
VTRSViatris Inc.54.4middling$20.2B
NBIXNeurocrine Biosciences, Inc.98.4strong$14.6B
ELANElanco Animal Health Incorporated84.0good$11.1B

Prices from DadFin's live feed (refreshed about every 15 minutes in the session); scores from the weekly run of Oct 4, 2026. Fundamentals as reported in the latest filings. Research, not investment advice.